The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Siiltibcy (rdESAT-6 and rCFP-10), a diagnostic aid for detection of Mycobacterium tuberculosis infection, including tuberculosis disease, in adults and children.

Tuberculosis (TB) is an infectious disease most commonly affecting the lungs, but capable of spreading to other parts of the body. It is usually transmitted through the air.

Siiltibcy is given as an injection in the skin of the forearm. It contains two active substances, rdESAT-6 and rCFP-10, which are proteins specific of Mycobacterium tuberculosis that have been produced in a laboratory.

If a person has been infected with Mycobacterium tuberculosis, her/his immune system will respond by producing cytokines (inflammatory proteins) which cause induratio

See Full Page